[SCHEDULE 13G] Lineage Cell Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Jorey Chernett filed a Schedule 13G reporting beneficial ownership of Lineage Cell Therapeutics, Inc. common stock. The filer reports owning 11,445,003 shares, representing 5.01% of the class, and states sole voting and dispositive power over those shares. The filing includes an alternate line reporting 11,455,003 shares for sole voting and dispositive power, creating an inconsistency in the reported share counts. The registrant's principal office is listed in Carlsbad, California.

The filer certifies the shares were not acquired to change or influence control of the issuer and signed the filing on 09/25/2025.

Insights

Securities Analyst

TL;DR: Routine passive 13G filing showing ~5% stake; reporting discrepancy requires clarification.

This Schedule 13G indicates an investor holding a stake at the regulatory threshold for disclosure, reporting 11,445,003 shares (5.01%). Holdings at or above 5% are material for shareholder visibility but do not necessarily indicate activist intent. The filer asserts sole voting and dispositive power and certifies the stake is not intended to influence control. The document contains an inconsistent alternate figure of 11,455,003 shares for voting/dispositive power; that discrepancy should be resolved to ensure accurate ownership metrics for market participants and filings processors.

Corporate Governance Expert

TL;DR: A standard passive ownership disclosure; governance impact appears neutral absent coordination or control intent.

The filing is presented under Schedule 13G, which typically denotes passive ownership. The certification that the position was not acquired to influence control reduces immediate governance concerns. From a governance perspective, a single holder at roughly 5% can matter for proxy contests or nominations only if combined with other shareholders or activist intent, neither of which is stated. The internal inconsistency in share counts (11,445,003 vs. 11,455,003) is a filing quality issue and may warrant an amendment for clarity.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lineage Cell Therapeutics, Inc.

(Name of Issuer)

Common

(Title of Class of Securities)

53566P109

(CUSIP Number)

09/22/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 53566P109

1

Names of Reporting Persons

Chernett Jorey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,445,003.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,445,003.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,445,003.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lineage Cell Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 2173 Salk Avenue, Ste. 200, Carlsbad, CALIFORNIA, 92008.
Item 2.
(a)	Name of person filing: Jorey Chernett
(b)	Address or principal business office or, if none, residence: 6222 Indianwood Trail, Bloomfield Hills, MI 48301
(c)	Citizenship: US
(d)	Title of class of securities: Common
(e)	CUSIP No.: 53566P109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 11,445,003
(b)	Percent of class: 5.01%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 11,455,003
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 11,455,003
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chernett Jorey

Signature:	/s/Jorey Chernett
Name/Title:	Individual
Date:	09/25/2025

FAQ

What stake in Lineage Cell Therapeutics (LCTX) does Jorey Chernett report?

The filing reports ownership of 11,445,003 shares, representing 5.01% of the class; an alternate line lists 11,455,003 shares for voting/dispositive power.

Does the Schedule 13G indicate activist intent for LCTX?

No. The filer certifies the shares were not acquired to change or influence control, consistent with a passive Schedule 13G filing.

Who signed the Schedule 13G and when was it filed for LCTX?

The filing was signed by Jorey Chernett on 09/25/2025.

Are there any issues with the ownership numbers in the filing?

Yes. The document shows both 11,445,003 and 11,455,003 as reported counts, indicating a discrepancy that may need correction.

Where is Lineage Cell Therapeutics' principal executive office listed in the filing?

The issuer's principal executive offices are listed at 2173 Salk Avenue, Ste. 200, Carlsbad, California 92008.